福泰制药重申2026年全年指引:GAAP与非GAAP研发、AI研发及销售管理费用预期不变

美股速递
Aug 04

福泰制药(Vertex Pharmaceuticals)再次确认其2026年全年财务指引。在涵盖GAAP及非GAAP口径下的研发支出、AI研发投入以及销售、一般及管理费用(SG&A)方面,该公司均维持此前预期不变,未作出任何调整。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10